Predicting and Responding to Emerging Viral Infections
January 1-4, 2026 | Location to be Determined
Scientific Organizers:
In Person
On Demand
January 1-4, 2026 | Location to be Determined
Scientific Organizers:
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Booking Function
Thursday, January 1, 2026
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Friday, January 2, 2026
Breakfast
7:00–8:00 AM
Welcome and Keynote Address
8:00–9:00 AM
Anthony S. Fauci †
Talk Title to be Announced
Talk Title to be Announced
Predictive Modeling and Surveillance
9:00–11:15 AM
Bethan Purse †, UK Centre for Ecology & Hydrology
Climate Change and Drivers of Emergence of Vector-Borne Viruses
Climate Change and Drivers of Emergence of Vector-Borne Viruses
Oliver Brady †, London School of Hygiene & Tropical Medicine
New Global Risk Maps for Dengue, Zika, Chikungunya and Yellow Fever
New Global Risk Maps for Dengue, Zika, Chikungunya and Yellow Fever
Houriiyah Tegally †, Stellenbosch University
The Role of Data Streams in Understanding Infection Dynamics
The Role of Data Streams in Understanding Infection Dynamics
Felicity Burt, University of The Free State
Diagnosis and Surveillance of Emerging Arboviruses in Africa
Diagnosis and Surveillance of Emerging Arboviruses in Africa
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Poster Setup
11:15–1:00 PM
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Coffee Available
4:30–5:00 PM
Pandemic Preparedness and Response Strategies
5:00–7:00 PM
Rick Arthur Bright †, Bright Global Health
Frontline Strategies: BARDA's Role in Combating Emerging Pathogens
Frontline Strategies: BARDA's Role in Combating Emerging Pathogens
Pei-Yong Shi †, GSK
GSK's Role in Strengthening Pandemic Preparedness
GSK's Role in Strengthening Pandemic Preparedness
Anish Nair †, Government Medical College
Nipah Virus - Smart Policy Changes that can Help Quell Pandemic Risk
Nipah Virus - Smart Policy Changes that can Help Quell Pandemic Risk
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Saturday, January 3, 2026
Breakfast
7:00–8:00 AM
Zoonoses 1 - One Health
8:00–11:00 AM
Martin Groschup †, Friedrich-Loeffler-Institut
Arbovirus and Zoonotic Virus Surveillance in Africa: Emphasizing a One Health Approach
Arbovirus and Zoonotic Virus Surveillance in Africa: Emphasizing a One Health Approach
Ian Brown †, Animal and Plant Health Agency
One Health Approach to Avian and Swine Influenza
One Health Approach to Avian and Swine Influenza
Linfa Wang †, Duke-NUS Medical School
Discovery of New Filoviruses/Other Viruses in Bats in Asia
Discovery of New Filoviruses/Other Viruses in Bats in Asia
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Career Roundtable
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Zoonoses 2 – Virus-Host Interactions
5:00–7:00 PM
Malik Peiris †, University of Hong Kong
Crossing Species: The Dynamics and Risks of Avian Influenza in Human Populations
Crossing Species: The Dynamics and Risks of Avian Influenza in Human Populations
Inger Damon †, Centers for Disease Control and Prevention
Elucidating Virus-Host Interactions in mPox: Mechanisms and Implications
Elucidating Virus-Host Interactions in mPox: Mechanisms and Implications
Christopher F. Basler, Icahn School of Medicine, Mt Sinai
Virus-Host Interactions of Filoviruses with a Focus on Ebola and Marburg
Virus-Host Interactions of Filoviruses with a Focus on Ebola and Marburg
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Sunday, January 4, 2026
Breakfast
7:00–8:00 AM
Vaccines
8:00–11:00 AM
Martina Schneider †, Valneva SE
IXCHIQ®, the First FDA-Approved Chikungunya Vaccine
IXCHIQ®, the First FDA-Approved Chikungunya Vaccine
Robert F. Garry †, Tulane University Health Sciences Center
Pathogenesis and Countermeasures for Lassa Fever
Pathogenesis and Countermeasures for Lassa Fever
George Warimwe †, University of Oxford
Combating Rift Valley Fever - ChAdOx1 Rift Valley Fever Vaccine Safety and Immunogenicity: Phase 1 Trial in Adults
Combating Rift Valley Fever - ChAdOx1 Rift Valley Fever Vaccine Safety and Immunogenicity: Phase 1 Trial in Adults
Kizzmekia S. Corbett-Helaire †, Harvard T.H. Chan School of Public Health
Preparing for a Pandemic: Lessons from COVID Vaccines and Applications to Other Viral Diseases
Preparing for a Pandemic: Lessons from COVID Vaccines and Applications to Other Viral Diseases
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Coffee Available
4:30–5:00 PM
Therapeutics
5:00–6:45 PM
Laura M. Walker †, Moderna
Advancing Infectious Disease Treatment: The Role of mRNA Therapeutics
Advancing Infectious Disease Treatment: The Role of mRNA Therapeutics
James E. Crowe, Jr. †, Vanderbilt University Medical Center
Small Biotech, Big Impact: Discovering Novel Therapies for Emerging Viruses
Small Biotech, Big Impact: Discovering Novel Therapies for Emerging Viruses
Suresh Mahalingam, Griffith University
Advancements in Drug Repurposing and New Therapeutics for Arthritogenic Alphaviruses: Tackling Acute and Chronic Disease
Advancements in Drug Repurposing and New Therapeutics for Arthritogenic Alphaviruses: Tackling Acute and Chronic Disease
Alina Baum, Regeneron Pharmaceuticals
Filovirus Therapeutic Antibodies
Filovirus Therapeutic Antibodies
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions
6:45–7:00 PM
Social Hour with Lite Bites
7:00–8:00 PM
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Monday, January 5, 2026
Departure
12:00–11:59 PM
Subscribe for Updates